

Figure 1

Plasmid Name	GENE	Parental Plasmid	Promoter/Enhancer	Terminator
VR1223	Firefly Lux	VR1012*	CMV	BGH
VR1412	Bacterial LacZ	VR1012*	CMV	BGH
VR2901	Mouse EPO	VR1012*	CMV	BGH
VR2996	Mouse EPO	VR1012	MV/Desmin	BGH
VR3301	Human SEAP	VR1012*	CMV	BGH
VR3502	Rat proinsulin	VR1012*	CMV	BGH
VR4151	Human IFN-omega	VR1055	CMV	mRBG
VR4700	Influenza NP	VR1255**	CMV	mRBG
VR1418	Bacterial LacZ	VR1043	RSV	BGH
VR1255	Firefly Lux	VR1223	CMV	mRBG

Intermediate plasmids

VR1012	none	V1J***	CMV	BGH
VR1043	none	VR1343	RSV	BGH
VR1055	none	VR1255	CMV	mRBG

Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 3




Figure 4





Figure 5






Figure 6.

Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13




Figure 14





Figure 15






Figure 16

CTL activity is not inhibited when pDNA + poloxamer is administered




Figure 16 D

effects on IFN α pDNA mediated anti-tumor efficacy




Figure 17







Figure 18

Figure 19



Day 3 luciferase expression after intramuscular administration of VR1255 \pm poloxamer (F68)

A



Day 3 luciferase expression after intramuscular administration of VR1255 \pm poloxamer (25R2)

B




Figure 20

Hematocrit levels after a single dose (1 μ g) of VR2901 \pm poloxamer 25R2




Fig 22

HCT levels after administration of VR2996 + Poloxamer F68





Fig 23

DNA dose response after injection of VR1255 ± poloxamer (25R2)



F_{14, 24}

TOEPLITZ INSTITUTE

Time course of expression after delivery of VR1255 ± 25R2 (0.01%)




Figure 25

Transfection of mouse rectus femoris with VR1412 (pBgal)
± poloxamer 25R2 (0.01%)




Figure 26

Targeted injections of 50 μ g β -gal pDNA
into murine rectus femoris
(10 μ m section stained with x-gal)

